TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males: Ages: 12 - less than 18 years.~* Bone age less than 14 ½ years at study initiation.~* Presence of puberty.~* Idiopathic short stature will be defined as a short child equal or less than -2SD for height, with normal GH responses to stimuli (\> or = 5ng/ml to at least 2 secretagogues) or a normal IGF-I and BP-3, normal body proportions and no other identifiable growth pathology.~* Accurate growth data for at least 6 months at baseline is available.~Exclusion Criteria:~* Chronic illnesses.~* Chronic use of glucocorticosteroids.~* Previous use of hormonal treatment with AIs, sex steroids or GH in the preceding 6 months.~* Birth weight small for gestational age (SGA).

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Aromatase Inhibitor (Type: ACTIVE_COMPARATOR): Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
- Growth Hormone (Type: ACTIVE_COMPARATOR): Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
- Aromatase Inhibitor and Growth Hormone (Type: ACTIVE_COMPARATOR): Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pulse Pressure and Post-epidural Fetal Heart Rate Changes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton pregnancy with gestational age ≥ 35 weeks~* Admission for delivery~* Age 18 or older~* Desires neuraxial analgesia in labor~* No exclusion criteria~* Maternal pulse pressure \< 45 mmHg on admission (verified by repeat blood pressure)~* Category 1 FHT on admission/prior to epidural placement~* Epidural placement within 6 hours of admission to Labor and Delivery~Exclusion Criteria:~* Multiple gestation~* Intrauterine growth restriction~* Hypertensive disorders (gestational hypertension, chronic hypertension, and preeclampsia/eclampsia)~* Gestational or pregestational diabetes mellitus~* Substance abuse~* Intrauterine fetal demise~* Congenital or chromosomal fetal abnormalities~* Category II or III FHR tracing on admission to L\&D (pre-epidural)~* Contraindication to neuraxial aesthesia (e.g. thrombocytopenia)~* Maternal cardiomyopathy, congenital heart disease, active pulmonary edema or any other underlying maternal cardiopulmonary condition that increases the risk of pulmonary edema~* Maternal renal insufficiency (serum creatinine \> 1.0)~* Maternal hypotension (as defined in secondary outcomes below) prior to epidural placement

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Standard IV Preload (Type: NO_INTERVENTION): Patients in this arm will receive 500mL of Lactated Ringer's solution, which is the standard IV fluid preload used on Labor and Delivery at MetroHealth Medical Center
- Volume Replacement IV Preload (Type: EXPERIMENTAL): Patients in this arm will receive 1500mL of Lactated Ringer's solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 1 or 2 Diabetes Mellitus treated with diet or medication~* Clinically or microbiologically documented foot infection below the knee~* Osteomyelitic bone must be removed within 48 hours of study entry~Exclusion Criteria:~* Uncomplicated skin infections~* Infected burn wounds~* Necrotizing fascitis~* Wounds with gangrene that cannot be removed with debridement~* Infections of prosthetic materials~* Foreign materials that can not be removed by surgical debridement~* Patients with another antibiotic 3 days prior to enrollment without evidence of treatment failure and presence of a positive culture~* Insufficient blood flow to the limb requiring a revascularization procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients should fulfill DSM-IV criteria for dementia (APA, 1994)~* Patients should fulfill criteria for AD with cerebrovascular disease according to NINDS-AIREN criteria (Román et al., 1993)~* The severity of dementia should be mild to moderate, as defined by MMSE score between 10 and 26 (inclusive)~* Patients (and their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.~Exclusion Criteria:~* History of neurodegenerative disorders such as Parkinson's disease, Pick's disease or Huntington's chorea, Down's syndrome, Creutzfeldt-Jacob disease. Patients who have mild extrapyramidal signs, for which no treatment is required, are not excluded from the trial~* History of liver or renal insufficiency~* significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, psychiatric, or metabolic disturbances in the past 6 months~* Patients who have previously received M1 agonists or cholinesterase inhibitors (tacrine, donepezil, metrifonate, rivastigmine) for treatment of Alzheimer's disease, no matter if approved or experimental can be included in this trial provided there was at least a washout period of 60 days prior to the screening assessments~* History of drug or alcohol abuse within the last year or prior prolonged history~* History of severe drug allergy or hypersensitivity~* including recorded hypersensitivity to cholinesterase inhibitors, choline agonists or similar agents, or bromide~* Subjects who have previously been enrolled in other galantamine trials.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Galantamine + Nimodipine (Type: EXPERIMENTAL): None
- Galantamine + Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with HCC who received curative liver resection (R0)and with positive expression of HAb18G/CD147 in the HCC tissues~2. Karnofsky Performance Score performance over 60~3. The functions of the kidney, heart and lung and the blood system are normal and fittable for Licardin therapy.~4. The liver function is of grade A or B in Child-Pugh classification.~5. Patients give consent to the test.~Exclusion Criteria:~1. Negative expression of HAb18G/CD147 in the HCC tissues~2. Allergic history to biologic products(Licartin)~3. Any of the situation list below: WBC less than 2000/ml, Hb less than 90g/L or PLT less than 50000/ml, bilirubin level more than 2.5 times the upper limit of normal value, serum albumin less than 32 g/l.~4. Severed disease of the heart, lung, kidney, brain and blood system.~5. Other severed disease might affect the trial .~6. Patients would not sign the consent to the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Licartin (Type: EXPERIMENTAL): patients who receive Licartin therapy after liver resection
- placebo (Type: NO_INTERVENTION): control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive Licartin therapy after liver resection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Registry of AngioJet Use in the Peripheral Vascular System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient has been treated in the peripheral vascular system with any of the AngioJet System catheters.~* Patient has provided appropriate consent/authorization per the site's institutional policy and procedure.~Exclusion Criteria:~* Patient has previously been enrolled in either the PEARL Registry or the PEARL II Registry in the last 12months.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Limb Ischemia (Type: None): Patients presenting with limb ischemia for treatment
- Deep Vein Thrombosis (Type: None): Patients presenting with deep vein thrombosis for treatment
- Hemodialysis Access (Type: None): Patients presenting with thrombosed hemodialysis access for treatment
- Other Thrombotic Conditions (Type: None): Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Heart Outcomes Prevention Evaluation-3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged \> 60 years and men \> 55 years~* At least one additional CV risk factor including:~* Waist/hip ratio ≥ 0.90 in men and ≥ 0.85 in women;~* History of current or recent smoking (regular tobacco use within 5 years)~* Low HDL cholesterol~* Dysglycemia~* Renal dysfunction~* Family history of premature CHD in first degree relatives~Exclusion Criteria:~* Documented clinically manifest atherothrombotic CVD~* Clear indication or contraindication for statin and/or ARB or ACE inhibitor and/or thiazide diuretic therapy~* Symptomatic hypotension~* Chronic liver disease~* Inflammatory muscle disease~* Renal impairment~* Concurrent treatment with cyclosporine or a condition likely to result in organ transplantation and the need for cyclosporine~* Concurrent treatment with a statin, fibrate, angiotensin receptor blocker, ACE inhibitor, or a thiazide diuretic~* Other serious medical illness likely to interfere with study participation or with the ability to complete the trial~* Significant psychiatric illness, senility, dementia, alcohol or substance abuse, which could impair the ability to provide informed consent and to adhere to the trial procedures~* Concurrent use of an experimental pharmacological agent

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Rosuvastatin (Type: PLACEBO_COMPARATOR): Rosuvastatin 10 mg vs placebo
- Candesartan/HCT (Type: PLACEBO_COMPARATOR): Candesartan 16 mg/HCT 12.5 mg vs placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety of Naldemedine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Subjects aged 18 to 80 years inclusive at the time of informed consent~2. Subjects must have non-malignant chronic pain treated and must have opioid induced constipation (OIC)~3. Subjects must be treated with a stable opioid regimen at a total daily dose on average of ≥ 30 mg equivalents of oral morphine sulfate~4. Subjects may or may not be on a routine laxative regimen at the time of Screening~Exclusion Criteria~1. Evidence of significant structural abnormalities of the gastrointestinal (GI) tract~2. Evidence of active medical diseases affecting bowel transit~3. History of pelvic disorders that may be a cause of constipation~4. Surgery (except for minor procedures) within 60 days of Screening~5. History of chronic constipation prior to starting analgesic medication or any potential non-opioid cause of bowel dysfunction that may be a major contributor to the constipation (e.g. mechanical GI obstruction)~6. Subjects who have never taken laxatives for the treatment of OIC~7. Current use of any prohibited medication including opioid antagonists, partial or mixed agonists/antagonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Naldemedine (Type: EXPERIMENTAL): Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo tablets orally once daily for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be practicing specific forms of birth control on study treatment, or be post-menopausal for more than 2 years or surgically sterile~* Chronic hepatitis C, genotype 1b-infection (HCV RNA level greater than or equal to 10,000 IU/mL at screening)~* Subject's hepatitis C virus genotype is subgenotype 1b at Screening without co infection with any other genotype/subgenotype.~Exclusion Criteria:~* Significant liver disease with any cause other than HCV as the primary cause~* Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody~* Positive screen for drugs or alcohol~* Use of contraindicated medications within 2 weeks of dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 and ABT-333, Plus RBV (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
- ABT-450/r/ABT-267 and ABT-333 (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stage II or III multiple myeloma according to Durie and Salmon criteria.~* Patients between 65 and 75 years of age~* Previously untreated patients~Exclusion Criteria:~* Prior history of another neoplasm (except basocellular cutaneous or cervical epithelioma)~* Primary or associated amyloidosis~* World Health organisation performance index of at least 3~* Significant renal insufficiency with creatinine serum levels of 5.0 mg per deciliter or more~* Cardiac or hepatic dysfunction~* Cerebral circulatory insufficiency~* Absolute contraindication to corticosteroids~* Peripheral neuropathy~* HIV or hepatitis B or C positivity~* Patients who had geographic, social or psychological conditions which might prevent adequate follow-up

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1. The patient have age more equal 18 year on enrollment date. 2. The patient get the dialysis of 3 times per week 3. The parathyroid hormone level greater than or equal to 800 pg per mL during the screening 4.The calcium level in the blood is greater than or equal to 9 mg per dL.~Exclusion Criteria:~1. The patient had parathyroid gland surgery.~2. The patient have a history of seizures within 12 weeks before randomized.~3. The patient is scheduled for surgery the kidney~4. The patient will expected parathyroid gland surgery within 6 months~5. The liver function have abnormalities, including SGOT, SGPT, more than two fold~6. The patient had history received a drug of bisphosphonates group or expected to be received during the study.~7. The patient had a history of cancer. Pregnant women. Lactating women. And with sepsis -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Regpara (Type: EXPERIMENTAL): calcium sensing receptor agonist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Network-Level Effects of Nitrous Oxide in the Human Brain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Body mass index \<30~2. Must be right-handed~3. Must be capable of giving written informed consent~Exclusion Criteria:~1. History of obstructive sleep apnea;~2. History of a difficult airway with a previous anesthetic~3. Gastroesophageal reflux;~4. Hypertension or other cardiovascular abnormalities;~5. Pulmonary hypertension;~6. History of recreational drug use;~7. History of chronic alcohol abuse~8. Having any chronic medical illness involving pain;~9. History of major depression;~10. History of psychosis or bipolar disorder;~11. History of methylenetetrahydrofolate reductase deficiency;~12. History of a known hypersensitivity to ketamine, midazolam, Zofran, labetalol or glycopyrrolate~13. History of seizures or other neurologic disorders;~14. Pregnant or nursing mothers;~15. Tattoos on the head or neck region - all other tattoos are subject to determination by investigators;~16. Contraindications to neuroimaging methods;~17. Any impairment, activity or situation that in the judgment of the Study Coordinator or Principal Investigators would prevent satisfactory completion of the study protocol.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Nitrous Oxide - inhaled (Type: EXPERIMENTAL): Each volunteer will participate in one scanning visit in which simultaneous functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanalgesic levels (35% inhaled concentration) over 40 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven epithelial ovarian cancer, epithelial fallopian tube cancer, or primary peritoneal cancer~* Prior treatment with only 1 platinum based chemotherapy regimen~* Eastern Cooperative Oncology Group status of not more than 2~* Progression more than 6 months after the start of initial chemotherapy treatment~Exclusion Criteria:~* Treatment with more than 1 prior chemotherapy regimen~* Progression within 6 months after starting initial chemotherapy~* Prior exposure to anthracyclines~* Unwilling or unable to have central venous catheter~* Known clinically relevant central nervous system metastasis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DOXIL + trabectedin (Type: EXPERIMENTAL): Combination arm - Trabectedin + DOXIL: DOXIL 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks. patients will be premedicated with 20 mg dexamethasone or its equivalent IV infusion over 30 minutes prior to the DOXIL infusion.
- DOXIL (Type: ACTIVE_COMPARATOR): Monotherapy arm - DOXIL: 50 mg/m2 IV infusion over 90 minutes every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete